@article {1428,
	title = {The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects.},
	journal = {The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions},
	volume = {11},
	year = {2002},
	month = {2002 Winter},
	pages = {66-74},
	abstract = {Methadone pharmacokinetics were determined in an open-label, within subject study in 16 methadone-maintained, non-HIV-infected subjects prior to and following administration of one lamivudine 150-mg/zidovudine 300-mg combination tablet to determine whether this antiretroviral therapy alters methadone serum concentrations. No significant differences in the mean area under the serum concentration-time curve (AUC(0-24h); 8,753 +/- 4,280 vs. 8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs. 10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected. These results suggest that methadone dose change is not likely to be necessary for patients treated with lamivudine/zidovudine combination pharmacotherapy.},
	keywords = {Adolescent, Adult, Anti-HIV Agents, Drug Combinations, Female, HIV Seropositivity, Humans, Lamivudine, Male, Methadone, Middle Aged, Narcotics, Opioid-Related Disorders, Zidovudine},
	issn = {1055-0496},
	author = {Rainey, Petrie M and Friedland, Gerald H and Snidow, Jerry W and McCance-Katz, Elinore F and Mitchell, Susan M and Andrews, Laurie and Lane, Barbara and Jatlow, Peter}
}
